-
公开(公告)号：US10463642B2
公开(公告)日：2019-11-05
申请号：US15395977
申请日：2016-12-30
Applicant: Vijaykumar Rajasekhar
Inventor： Vijaykumar Rajasekhar
IPC: A61K45/06 , A61K31/225
Abstract: Pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating heart failure diseases such heart failure with preserved ejection fraction (HFPEF) alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.
-
公开(公告)号：US20190167638A1
公开(公告)日：2019-06-06
申请号：US16266548
申请日：2019-02-04
Applicant: Vijaykumar Rajasekhar
Inventor： Vijaykumar Rajasekhar
IPC: A61K31/4015 , A61K45/06
Abstract: Methods and pharmaceutical compositions comprising one or more prodrugs (e.g., aminoalkyl prodrugs) of monomethyl fumarate (MMF) thereof are provided herein for the treatment of a heart failure disease, including heart failure with preserved ejection fraction. The compounds of the present disclosure are configured to be converted in vivo, upon oral administration, to monomethyl fumarate. Upon conversion, the active moiety (i.e., monomethyl fumarate) of various embodiments is effective in treating subjects suffering from a heart failure disease, including heart failure with preserved ejection fraction.
-
公开(公告)号：US20170258751A1
公开(公告)日：2017-09-14
申请号：US15457908
申请日：2017-03-13
Applicant: Vijaykumar Rajasekhar
Inventor： Vijaykumar Rajasekhar
IPC: A61K31/232
CPC classification number: A61K31/232
Abstract: Pharmaceutical compositions comprising Fatty Acid Fumarate Derivatives, and methods of using Fatty Acid Fumarate Derivatives and pharmaceutical compositions thereof for treating heart failure diseases, including heart failure with preserved ejection fraction (HFPEF), comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.
-
4.发明申请公开(公告)号：US20110112513A1
公开(公告)日：2011-05-12
申请号：US12768628
申请日：2010-04-27
Applicant: Jerome E. Hester , Anthony J. ABBATE , Richard E. KAUFMAN , David C. GALE , Gail M. ZALER , Bin HUANG , Lisa EARNHARDT , Vijaykumar RAJASEKHAR
Inventor： Jerome E. Hester , Anthony J. ABBATE , Richard E. KAUFMAN , David C. GALE , Gail M. ZALER , Bin HUANG , Lisa EARNHARDT , Vijaykumar RAJASEKHAR
CPC classification number: A61L31/16 , A61B17/04 , A61B17/06166 , A61B17/064 , A61B17/0644 , A61B17/068 , A61B17/08 , A61B17/083 , A61B17/26 , A61B17/3468 , A61B2017/0073 , A61B2017/00893 , A61B2017/06176 , A61B2017/0641 , A61B2017/0647 , A61B2017/0649 , A61B2090/3987 , A61B2090/3991 , A61L17/10 , A61M31/00 , A61M31/002 , A61M37/0069
Abstract: Described here are devices and methods for treating one or more conditions or symptoms associated with a tonsil procedure. In some variations, a drug-releasing device may be at least partially delivered to one or more tonsillar tissues before, during, or after a tonsil procedure. In some variations, the drug-releasing device may be configured to be biodegradable. In other variations, the drug-releasing device may comprise one or more hemostatic materials or one or more adhesives. The drug-releasing device may be configured to release one or more drugs or agents, such as, for example, one or more analgesics, local anesthetics, vasoconstrictors, antibiotics, combinations thereof and the like.
Abstract translation: 这里描述了用于治疗与扁桃体过程相关的一种或多种病症或症状的装置和方法。 在一些变型中，药物释放装置可以在扁桃体手术之前，期间或之后至少部分递送至一个或多个扁桃体组织。 在一些变型中，药物释放装置可以被配置为可生物降解的。 在其它变型中，药物释放装置可以包括一种或多种止血材料或一种或多种粘合剂。 药物释放装置可以被配置为释放一种或多种药物或药剂，例如一种或多种止痛剂，局部麻醉剂，血管收缩剂，抗生素，其组合等。
-
公开(公告)号：US20170216242A1
公开(公告)日：2017-08-03
申请号：US15395977
申请日：2016-12-30
Applicant: Vijaykumar Rajasekhar
Inventor： Vijaykumar Rajasekhar
IPC: A61K31/225 , A61K45/06
CPC classification number: A61K31/225 , A61K45/06
Abstract: Pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating heart failure diseases such heart failure with preserved ejection fraction (HFPEF) alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20170056356A1
公开(公告)日：2017-03-02
申请号：US15249744
申请日：2016-08-29
Applicant: Vijaykumar Rajasekhar
Inventor： Vijaykumar Rajasekhar
CPC classification number: A61K31/22 , A61K9/2833 , A61K31/225 , A61K45/06
Abstract: Pharmaceutical preparations and methods for treating or preventing a heart failure disease, including heart failure with preserved ejection fraction (HFPEF), with one or more dialkyl fumarates alone or in combination with one or more second agents are provided herein. In some embodiments, the pharmaceutical preparations are in the form of micro-tablets or pellets.
Abstract translation: 本文提供了用于治疗或预防心力衰竭疾病的药物制剂和方法，包括具有保留的射血分数（HFPEF）的心力衰竭，单独使用一种或多种富马酸二烷基酯或与一种或多种第二药剂组合。 在一些实施方案中，药物制剂是微片剂或丸剂的形式。
-
公开(公告)号：US20170014625A1
公开(公告)日：2017-01-19
申请号：US15277946
申请日：2016-09-27
Applicant: Kathryn H. ROSENBLUTH , Scott Lee DELP , John PADERI , Vijaykumar RAJASEKHAR , Tahel ALTMAN
Inventor： Kathryn H. ROSENBLUTH , Scott Lee DELP , John PADERI , Vijaykumar RAJASEKHAR , Tahel ALTMAN
CPC classification number: A61N1/36014 , A61N1/025 , A61N1/0456 , A61N1/0476 , A61N1/0492 , A61N1/08 , A61N1/18 , A61N1/36067
Abstract: A peripheral nerve stimulator can be used to stimulate a peripheral nerve to treat essential tremor, Parkinson tremor, and other forms of tremor. The peripheral nerve stimulator can be either a noninvasive surface stimulator or an implanted stimulator. Stimulation can be electrical, mechanical, or chemical. Stimulation can be delivered using either an open loop system or a closed loop system with feedback.
Abstract translation: 外周神经刺激器可用于刺激周围神经来治疗原发性震颤，帕金森震颤和其他形式的震颤。 周围神经刺激器可以是非侵入性表面刺激器或植入的刺激器。 刺激可以是电，机械或化学。 刺激可以使用开环系统或具有反馈的闭环系统来实现。
-
公开(公告)号：US20160354444A1
公开(公告)日：2016-12-08
申请号：US15173398
申请日：2016-06-03
Applicant: Vijaykumar Rajasekhar
Inventor： Vijaykumar Rajasekhar
CPC classification number: A61K38/2257 , A61K9/0021 , A61K9/0075 , A61K9/008 , A61K47/60
Abstract: Described herein are pharmaceutical compositions for the treatment of sexual dysfunction in an individual. In some embodiments, the pharmaceutical composition includes a prolactin variant having a glycine residue at position 129 substituted with an amino acid other than glycine. In one embodiment, the amino acid is arginine. In one embodiment, the prolactin variant further comprises an N-terminal deletion. In one embodiment, the prolactin variant is conjugated to a H(OCH2CH2)nOH molecule (e.g., n equals any number from 1 to 6). In some embodiments, the pharmaceutical composition is delivered to the individual by a microneedle patch or an inhalable formulation.
Abstract translation: 本文描述的是用于治疗个体性功能障碍的药物组合物。 在一些实施方案中，药物组合物包含催乳素变体，其在129位被甘氨酸除非甘氨酸以外的氨基酸取代。 在一个实施方案中，氨基酸是精氨酸。 在一个实施方案中，催乳素变体还包含N-末端缺失。 在一个实施方案中，催乳素变体与H（OCH 2 CH 2）n OH分子缀合（例如，n等于1至6的任何数）。 在一些实施方案中，药物组合物通过微针补片或可吸入制剂递送至个体。
-
公开(公告)号：US08763222B2
公开(公告)日：2014-07-01
申请号：US12512855
申请日：2009-07-30
Applicant: Anthony J. Abbate , Bin Huang , Gail M. Zaler , David C. Gale , Richard E. Kaufman , Vijaykumar Rajasekhar
Inventor： Anthony J. Abbate , Bin Huang , Gail M. Zaler , David C. Gale , Richard E. Kaufman , Vijaykumar Rajasekhar
CPC classification number: A61F2/95 , A61F2/0095 , A61F2/24 , A61F2002/9511 , A61F2002/9522 , B25B27/10 , Y10T29/49908 , Y10T29/53657 , Y10T29/53709 , Y10T29/53783 , Y10T29/53991
Abstract: Described here are devices and methods for crimping self-expanding devices. The crimping devices may be useful for crimping a variety of different self-expanding devices (whether such devices are biodegradable or bio-durable). The crimping devices may have crimping members to engage the self-expanding device to reduce the device from an expanding configuration to an unexpanded configuration. The crimping member may comprise or include a suture, wire, ribbon, guiding hoop, pusher, prong, holding bar, balloon, jaws, combinations thereof, or the like. The crimping devices may also include or comprise a holding structure to hold the self-expanding device in an unexpanded or expanded configuration.
Abstract translation: 这里描述了用于卷曲自扩张装置的装置和方法。 卷曲装置可用于卷曲各种不同的自扩张装置（无论这种装置是可生物降解的还是生物耐久的）。 压接装置可以具有压接构件以接合自膨胀装置，以将装置从扩张构型减小到未膨胀构型。 压接构件可以包括或包括缝合线，线，带，引导环，推动器，插脚，保持杆，气球，钳口，其组合等。 压接装置还可以包括或包括用于将自膨胀装置保持在未膨胀或膨胀构型的保持结构。
-
公开(公告)号：US10213411B2
公开(公告)日：2019-02-26
申请号：US15249820
申请日：2016-08-29
Applicant: Vijaykumar Rajasekhar
Inventor： Vijaykumar Rajasekhar
IPC: A61K31/4015 , A61K45/06
Abstract: Methods and pharmaceutical compositions comprising one or more prodrugs (e.g., aminoalkyl prodrugs) of monomethyl fumarate (MMF) thereof are provided herein for the treatment of a heart failure disease, including heart failure with preserved ejection fraction. The compounds of the present disclosure are configured to be converted in vivo, upon oral administration, to monomethyl fumarate. Upon conversion, the active moiety (i.e., monomethyl fumarate) of various embodiments is effective in treating subjects suffering from a heart failure disease, including heart failure with preserved ejection fraction.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.02 seconds)
